New drug trial aims to control serious fatty liver disease
NCT ID NCT07249788
Summary
This study is testing the safety and effectiveness of a drug called Resmiterom for people with MASH, a serious type of fatty liver disease that can lead to scarring. It will involve 165 patients in Pakistan who have been diagnosed with MASH and at least one related health condition like diabetes or obesity. The main goal is to see if the drug can reduce liver scarring and fat, as measured by special scans and blood tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Liver transplant center, Holy family hospital
RECRUITINGRawalpindi, Punjab Province, Pakistan
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.